The most recent systematic review of randomized trials in patients with bone metastases has shown equal efficacy of single fraction (SF) and multiple fraction (MF) palliative radiation therapy in pain relief. It is important to determine the patient population to which the evidence applies. This study aims to examine the eligibility criteria of the studies included in the systematic review to define characteristics of "uncomplicated" bone metastases.
Introduction
Bone metastases are a common manifestation of cancer [1] . Most patients present with pain and impaired mobility, while others can develop complications such as pathological fractures and compression of the spinal cord or cauda equina [2] . Many randomized studies have been conducted to determine if a dose response exists for pain relief from palliative radiation therapy in patients with painful bone metastases. The most recent systematic review of these trials conclude the equivalency of single fraction (SF) and multiple fraction (MF) treatments for pain relief from "uncomplicated" bone metastases, though the meaning of the term is not explicitly stated in most of the examined studies [3] .
The United States national guidelines published by the American Society of Radiation Oncology and the American College of Radiology suggest that there are no differences between SF and MF dosing in palliative treatment for bone metastases [2, 4] , although definitions distinguishing between complicated and uncomplicated bone metastases were not consistently provided. In practice, most radiation oncologists consider bone metastases causing pathologic fractures or compression of the spinal cord and cauda equina to be complicated. Some also consider those with associated soft tissue components or those within weight bearing bones at high risk of fracture to be complicated as well, but operational definitions vary among practice settings.
A clearer definition of "uncomplicated bone metastases" is required to determine the patient population in which the results of the prospective randomized trials apply. Whereas a workgroup or committee could be established to explore this issue, the translation of existing data to practice patterns necessitates a comprehensive evaluation of the completed trials. So, the purpose of the current study was to examine the inclusion and exclusion Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/jbo criteria of the randomized studies as described in the recent systematic review , thereby clearly defining the characteristics of the patient population in which a SF is equivalent to MF for the palliation of "uncomplicated" bone metastases.
Materials and methods
Only fully published trials from the systematic review were included in the analysis, and therefore abstract by Kirkbride et al. [13] was omitted. Study by Amouzegar-Hashemi et al. [24] and abstract by Haddad et al. [29] used the same trial, and therefore the former was used in the analysis. Study by Steenland et al. [26] and follow-up by van der Linden et al. [18] used the same trial, and therefore the former was used in the analysis. Study by Kaasa et al. [28] and its follow-up by Sande et al. [27] also used the same trial, and therefore the former was used in the analysis.
The methods sections of 21 studies comparing SF to MF course of radiation therapy for painful bone metastases out of 25 studies included in the most recent systematic review of bone metastases treatment were examined by PMC, EW and NT for their patient inclusion and exclusion criteria .
Results
The inclusion and exclusion criteria of the 21 studies are listed in Table 1 . All 21 studies included patients with bone metastases, whereas all but one study specified painful bone metastases. Thirteen of the 21 studies required cytological or histological evidence of malignancy as part of the inclusion criteria, and 9 of these studies required radiographic evidence of bone metastases. Five of such studies did not specify the method of imaging, 1 specified X-ray, 2 specified X-ray or bone scan, and 1 specified X-ray, bone scan, CT or MRI. Only 2 studies limited accrual to patients with a previously specified primary tumor location, and only 2 studies included patients with pain deemed to have resulted from neuropathic pain.
Of the included 21 studies, 18 excluded patients with pathological fracture, of which 12 studies excluded patients with existing pathological fracture, and 6 studies excluded patients with either existing ("need of bone surgery" was interpreted as existing pathological fracture) or impending pathological fracture. Three of the studies excluded patients with pathological fracture specified the location of fracture in the long bone, and 1 study followed Mirel's criteria for measurement of impending fracture. Nine studies excluded patients presenting with spinal cord compression, and 3 studies excluded patients with either spinal cord or cauda equina compression. A total of 18 studies excluded patients who received previous radiation therapy, consisting of 17 studies which excluded patients who received radiation to the same treatment site, and 1 study which excluded patients who received any radiotherapy 10 weeks prior to the study.
Discussion
A systematic review showed that SF radiotherapy resulted in equivalent pain relief to MF courses of radiation therapy for patients with uncomplicated painful bone metastases [3] . However, in order to apply the findings of this paper to the appropriate patient population, a description for the term "uncomplicated bone metastases" is preferred. Based upon an analysis of inclusion/exclusion criteria for 21 prospective randomized studies, we suggest the following working definition: uncomplicated bone metastases are those unassociated with impending or existing pathologic fracture or existing spinal cord compression or cauda equina compression.
The strengths of this definition are its simplicity and its usefulness in translating existing data into daily practice. The shortcomings of this definition include the lack of uniform criteria to suggest an impending fracture as well as the variable definitions of spinal cord compression or cauda equina compression. Although 9 studies excluded patients with spinal cord compression alone, and 3 studies excluded patients with spinal cord compression or cauda equina compression, none provided a definition or associated symptoms of such conditions. Furthermore, only 4 studies by Roos et al. [19] , Hartsell et al. [20] , Safwat et al. [23] , and Foro Arnalot et al. [25] required clinical or radiological evidence of compression. Still, in spite of these nuances, the case can be made for conformity of treatment in patients whose clinical circumstances reside within the confines of this definition. Roos [19] Pathologically confirmed malignancy Plain X-ray or bone scan evidence of bone metastasis Pain or dysaesthesia predominantly of a neuropathic nature Life expectancy at least six weeks. Able to complete the pain assessments
Metastasis within the distribution of the neuropathic pain (e.g. In contrast, the use of SF and MF radiation therapy treatments vary in patients with complicated bone metastases. A randomized controlled trial by Patchell et al. evaluating the efficacy of direct decompressive surgery showed that decompressive surgical resection and post-operative MF radiation therapy (30 Gy in 10 fractions) combined is superior to radiation therapy alone for patients with cord compression by metastatic cancer restricted to a single area and fair to good motor function below the injury level [30] .
Furthermore, MF (median dose 30 Gy) in postoperative radiation therapy following stabilization of impending pathological fracture was associated with increased functional status, decreased failure of the prosthesis, and perhaps improved overall survival [31] . In another randomized trial by Maranzano et al., 8 Gy SF radiation therapy was shown to be effective in achieving palliation in patients with metastatic spinal cord compression by bone metastases and poor performance status. However, this may be Haddad [29] Adult with painful uncomplicated bone metastases Cord compression or existing or impending pathologic fracture attributed to the short life expectancy (6 months or less) of included patients, who would benefit from minimal toxicity and convenience of SF [32] . Moreover, a study by Roos et al. comparing SF and MF in patients with bone metastases presenting with neuropathic pain suggested SF was not as effective as MF in treating neuropathic pain, although it was not statistically significantly worse [19] .
It is important to recognize that our definition of uncomplicated bone metastases may be incomplete. Only 2 of the 21 studies in the updated review excluded patients presenting with neuropathic pain, a common complication of bone metastases. Therefore, we could not incorporate the absence of neuropathic pain into our definition. Furthermore, bone metastases with soft tissue mass were not excluded in any of the studies examined. As such, the absence of a soft tissue mass cannot be considered a characteristic of uncomplicated bone metastases. Only 1 study verified bone metastases through 3D imaging such as CT or MRI, and 12 studies did not require any radiographic evidence. Therefore, interpreting results of older studies should consider the lack of reliable radiographic evidence. Future trials may benefit from examining the bone metastases with soft tissue masses for a dose response phenomenon.
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